While Bristol-Myers Squibb Co has overperformed by 0.81%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BMY rose by 9.40%, with highs and lows ranging from $61.08 to $39.35, whereas the simple moving average jumped by 15.57% in the last 200 days.
On December 16, 2024, Jefferies Upgraded Bristol-Myers Squibb Co (NYSE: BMY) to Buy. Leerink Partners November 12, 2024d its ‘Market Perform’ rating to ‘Outperform’ for BMY, as published in its report on November 12, 2024. Citigroup’s report from October 25, 2024 suggests a price prediction of $55 for BMY shares, giving the stock a ‘Neutral’ rating. Bernstein also rated the stock as ‘Mkt Perform’.
Analysis of Bristol-Myers Squibb Co (BMY)
Investors in Bristol-Myers Squibb Co will get a return regardless of how the company performs over the next quarter since the company’s dividend stands at $2.42 per share. Further, the quarter-over-quarter increase in sales is 8.44%, showing a positive trend in the upcoming months.
One of the most important indicators of Bristol-Myers Squibb Co’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -31.46% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.09, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and BMY is recording 10.49M average volume. On a monthly basis, the volatility of the stock is set at 1.97%, whereas on a weekly basis, it is put at 1.64%, with a gain of 1.93% over the past seven days. Furthermore, long-term investors anticipate a median target price of $60.26, showing growth from the present price of $57.14, which can serve as yet another indication of whether BMY is worth investing in or should be passed over.
How Do You Analyze Bristol-Myers Squibb Co Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.08%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 77.71% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BMY shares are owned by institutional investors to the tune of 77.71% at present.
